Advanced Liver Cancer Market Size Forecasted To Achieve 3.78 Billion By 2029 With Steady Growth

"Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Advanced Liver Cancer Market Size and Projected Growth Rate?
The market size for advanced liver cancer has experienced a swift expansion in the preceding years. It is projected to increase from $1.89 billion in 2024 to $2.17 billion in 2025, with a compound annual growth rate (CAGR) of 15.2%. Factors contributing to the growth during the historic period include heightened awareness of liver cancer, a rise in the number of patients, a surge in the demand for targeted therapies, the expansion of healthcare infrastructure, and a growing preference for minimally invasive treatments.

In the upcoming years, the advanced liver cancer market is anticipated to experience significant expansion. The market is projected to reach $3.78 billion by 2029, with a compound annual growth rate (CAGR) of 14.8%. Factors contributing to this anticipated growth during the forecast period include the increasing occurrence of liver cancer, the rise in healthcare expenditure, the growing prevalence of genetic disorders, the heightened acceptance of precision medicine, and the upward trend in the use of screening and diagnostic tests. The predicted trend during the forecast period indicates an increase in the incorporation of artificial intelligence in treatment procedures, the creation of novel drugs and therapies, amplified research and development activities, advancements in targeted therapeutics, and a rising demand for personalized medicine.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20706

What Are the Major Segments in the Advanced Liver Cancer Market?
The advanced liver cancer market covered in this report is segmented -

1) By Test Type: Imaging Test, Biopsy, Genomic Test, Other Test Types
2) By Technology: Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, Other Technologies
3) By Distribution Channel: Direct Tenders, Retail Sales, Other Distribution Channel
4) By Application: Screening, Diagnostic And Predictive, Prognostic, Research
5) By End-User: Hospitals, Cancer Research Centers, Academic Institutes, Diagnostic Centers, Ambulatory Surgical Centers, Other End-Users

Subsegments:
1) By Imaging Test: Ultrasound, CT (Computed Tomography) Scan, MRI (Magnetic Resonance Imaging), PET (Positron Emission Tomography) Scan
2) By Biopsy: Needle Biopsy, Laparoscopic Biopsy, Surgical Biopsy
3) By Genomic Test: Next-Generation Sequencing (NGS), PCR (Polymerase Chain Reaction) Testing, Genetic Mutation Profiling
4) By Other Test Types: Serum Biomarker Testing, Liver Function Tests, Alpha-Fetoprotein (AFP) Test, Elastography Tests

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20706&type=smp

What Are The Driving Advanced Liver Cancer Market Evolution?
The advanced liver cancer market's growth is being fueled by the growing prevalence of long-term hepatitis infections. Such infections are protracted viral attacks lasting over six months, which can potentially lead to liver damage, cirrhosis, or liver cancer. Factors such as lack of adequate screening and vaccination, along with delayed treatment, are believed to contribute to the rise in long-term hepatitis infections. The predominant causes of liver cirrhosis and hepatocellular carcinoma (HCC), the most common type of liver cancer, are chronic infections with hepatitis B (HBV) or hepatitis C (HCV). In the long run, persistent viral infections can induce liver inflammation, leading to liver damage and eventually to cancer. As a consequence, as these infections persist in prevalence, the number of individuals at risk of developing advanced liver cancer raises. For instance, the World Health Organization, a Switzerland-based intergovernmental organization, reported in April 2024 that 254 million people worldwide were affected by chronic hepatitis B in 2022, with 1.2 million new cases emerging annually. Hence, the advanced liver cancer market's expansion is being primarily driven by the increasing occurrence of long-term hepatitis infections.

Which Firms Dominate The Advanced Liver Cancer Market Segments?
Major companies operating in the advanced liver cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Stryker Corporation, Agilent Technologies Inc., Eisai Co. Ltd., Jiangsu Hengrui Pharmaceutical Co. Ltd, Exelixis Inc., Sirtex Medical Limited, Eureka Therapeutics, Abbisko Therapeutics Co. Ltd., Binhui Biopharmaceutical Co. Ltd., Tempest Therapeutics Inc., Auransa Inc., Mina Alpha Limited, Jennere*x Inc.

What Trends Are Expected to Dominate the Acquired Autoimmune Hemolytic Anemia Market in the Next 5 Years?
Significant players in the advanced liver cancer market, such as AstraZeneca, are turning their attention towards the development of ground-breaking drugs like human monoclonal antibodies. This innovative method, designed to enhance treatment effectiveness and reduce side effects, replicates the immune system's role in fighting off malicious pathogens or cancer cells. It zeroes in on specific antigens on the surface of these damaging factors, sparking an immune response. In a stellar example from October 2022, the US Food and Drug Administration (FDA) gave approval to the human monoclonal antibodies combo of Imjudo (tremelimumab) and Imfinzi (durvalumab), developed by AstraZeneca for treating adult patients with inoperable hepatocellular carcinoma (HCC), the prevalent form of liver cancer. The FDA's decision was made in light of outcomes from the HIMALAYA Phase III study, which illustrated that the combined therapy cut the mortality risk by 22% compared to sorafenib. Notably, around 31% of patients given this treatment survived for three years, a marked improvement from the 20% survival rate in those given sorafenib. With the STRIDE regimen, patients receive a one-off dose of Imjudo, then regular doses of Imfinzi every four weeks, providing a novel treatment alternative for patients with limited options.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/advanced-liver-cancer--global-market-report

Which Is The Largest Region In The Advanced Liver Cancer Market?
North America was the largest region in the advanced liver cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced liver cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Advanced Liver Cancer Market?
2. What is the CAGR expected in the Advanced Liver Cancer Market?
3. What Are the Key Innovations Transforming the Advanced Liver Cancer Industry?
4. Which Region Is Leading the Advanced Liver Cancer Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments."

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
•LinkedIn: https://in.linkedin.com/company/the-business-research-company
•Twitter: https://twitter.com/tbrc_info
•YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.